-
Bicara Therapeutics :BCAX Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.
Location: Cambridge, Massachusetts, United States | Website: https://www.bicara.com | Industry: | Sector:
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
303.8M
Cash
489.7M
Avg Qtr Burn
-18.69M
Short % of Float
19.00%
Insider Ownership
0.43%
Institutional Own.
85.72%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ficerafusp alfa + Pembrolizumab Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 2/3 Data readout | |
Ficerafusp alfa Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 1 Data readout |